{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=High-Risk&page=13",
    "query": {
      "condition": "High-Risk",
      "page": 13
    },
    "page_size": 10
  },
  "pagination": {
    "page": 13,
    "page_size": 10,
    "total_count": 7258,
    "total_pages": 726,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=High-Risk&page=14&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=High-Risk&page=12&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-05T18:34:45.783Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03282396",
      "title": "Ibrutinib in Treating Participants With Untreated High Risk Smoldering Mantle Cell Lymphoma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Mantle Cell Lymphoma"
      ],
      "interventions": [
        {
          "name": "Ibrutinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2020-06-08",
      "completion_date": "2028-02-28",
      "has_results": false,
      "last_update_posted_date": "2026-07-16",
      "last_synced_at": "2026-11-05T18:34:45.783Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03282396"
    },
    {
      "nct_id": "NCT07723703",
      "title": "Phase 1 Open-label Study of AMX-883 Alone in Participants With AML and High-risk MDS and in Combination in Participants With AML",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Acute Myeloid Leukaemia",
        "High Risk Myelodysplastic Syndrome"
      ],
      "interventions": [
        {
          "name": "AMX-883",
          "type": "DRUG"
        },
        {
          "name": "Posaconazole",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Amphista Therapeutics Ltd",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 54,
      "start_date": "2026-09-16",
      "completion_date": "2029-04-30",
      "has_results": false,
      "last_update_posted_date": "2026-11-02",
      "last_synced_at": "2026-11-05T18:34:45.783Z",
      "location_count": 2,
      "location_summary": "New York, New York • Fairfax, Virginia",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Fairfax",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07723703"
    },
    {
      "nct_id": "NCT02610283",
      "title": "A Study to Evaluate Efficacy and Safety of QPI-1002 for Prevention of Acute Kidney Injury Following Cardiac Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Kidney Injury"
      ],
      "interventions": [
        {
          "name": "QPI-1002",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Quark Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "45 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "45 Years and older"
      },
      "enrollment_count": 341,
      "start_date": "2015-12",
      "completion_date": "2018-04",
      "has_results": false,
      "last_update_posted_date": "2019-01-10",
      "last_synced_at": "2026-11-05T18:34:45.783Z",
      "location_count": 20,
      "location_summary": "Tucson, Arizona • Gainesville, Florida • Jacksonville, Florida + 16 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Oak Lawn",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02610283"
    },
    {
      "nct_id": "NCT00071513",
      "title": "Middle School to High School Transition Project: Depression and Substance Abuse Prevention",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Depression",
        "Substance-Related Disorders"
      ],
      "interventions": [
        {
          "name": "CAST-T/HSTS",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Brief Intervention",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "University of Washington",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "15 Years",
        "sex": "ALL",
        "summary": "12 Years to 15 Years"
      },
      "enrollment_count": 497,
      "start_date": "2003-03",
      "completion_date": "2007-06",
      "has_results": true,
      "last_update_posted_date": "2016-08-17",
      "last_synced_at": "2026-11-05T18:34:45.783Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00071513"
    },
    {
      "nct_id": "NCT07053059",
      "title": "Phase 2 Study Assessing the Clinical Activity and Safety of Obecabtagene Autoleucel as a Consolidation in Patients With Newly Diagnosed High-risk B-cell Acute Lymphocytic Leukemia (ALL)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Lymphocytic Leukemia (ALL)"
      ],
      "interventions": [
        {
          "name": "Obecabtagene autoleucel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2025-08-26",
      "completion_date": "2030-05-31",
      "has_results": false,
      "last_update_posted_date": "2026-08-12",
      "last_synced_at": "2026-11-05T18:34:45.783Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07053059"
    },
    {
      "nct_id": "NCT00879762",
      "title": "High Dose IMVAMUNE® in Vaccinia-Naive Individuals",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Smallpox"
      ],
      "interventions": [
        {
          "name": "MVA Smallpox Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "38 Years",
        "sex": "ALL",
        "summary": "18 Years to 38 Years"
      },
      "enrollment_count": 91,
      "start_date": "2009-05-29",
      "completion_date": "2011-03-09",
      "has_results": true,
      "last_update_posted_date": "2025-06-13",
      "last_synced_at": "2026-11-05T18:34:45.783Z",
      "location_count": 2,
      "location_summary": "Iowa City, Iowa • St Louis, Missouri",
      "locations": [
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00879762"
    },
    {
      "nct_id": "NCT05522803",
      "title": "Can Transcranial Magnetic Stimulation Decrease Food Reinforcement",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Obesity"
      ],
      "interventions": [
        {
          "name": "TMS followed by sham TMS",
          "type": "DEVICE"
        },
        {
          "name": "Sham TMS followed by TMS",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Hartford Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 12,
      "start_date": "2023-01-26",
      "completion_date": "2024-06",
      "has_results": false,
      "last_update_posted_date": "2024-02-28",
      "last_synced_at": "2026-11-05T18:34:45.783Z",
      "location_count": 1,
      "location_summary": "Hartford, Connecticut",
      "locations": [
        {
          "city": "Hartford",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05522803"
    },
    {
      "nct_id": "NCT02199925",
      "title": "An Open-Label Study to Evaluate the Efficacy of High-Dose Gammaplex in Children on the Autism Spectrum",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Autism",
        "Autistic Disorder",
        "Asperger's Disorder",
        "PDD",
        "Pervasive Developmental Disorder"
      ],
      "interventions": [
        {
          "name": "Gammaplex 5%",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Isaac Melamed",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "4 Years",
        "maximum_age": "12 Years",
        "sex": "ALL",
        "summary": "4 Years to 12 Years"
      },
      "enrollment_count": 30,
      "start_date": "2013-06",
      "completion_date": "2015-07",
      "has_results": false,
      "last_update_posted_date": "2015-04-16",
      "last_synced_at": "2026-11-05T18:34:45.783Z",
      "location_count": 1,
      "location_summary": "Centennial, Colorado",
      "locations": [
        {
          "city": "Centennial",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02199925"
    },
    {
      "nct_id": "NCT00857389",
      "title": "Thiotepa-Clofarabine-Busulfan With Allogeneic Stem Cell Transplant for High Risk Malignancies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Stem Cell Transplantation",
        "Leukemia",
        "Lymphoma"
      ],
      "interventions": [
        {
          "name": "Thiotepa",
          "type": "DRUG"
        },
        {
          "name": "Clofarabine",
          "type": "DRUG"
        },
        {
          "name": "Busulfan",
          "type": "DRUG"
        },
        {
          "name": "Allogeneic Stem Cell Transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "Thymoglobulin (ATG)",
          "type": "DRUG"
        },
        {
          "name": "G-CSF (Filgrastim)",
          "type": "DRUG"
        },
        {
          "name": "Tacrolimus",
          "type": "DRUG"
        },
        {
          "name": "Methotrexate",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Mesna",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "Up to 60 Years"
      },
      "enrollment_count": 60,
      "start_date": "2009-03-02",
      "completion_date": "2019-03-09",
      "has_results": true,
      "last_update_posted_date": "2020-04-07",
      "last_synced_at": "2026-11-05T18:34:45.783Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00857389"
    },
    {
      "nct_id": "NCT04381923",
      "title": "COVIDNOCHE Trial (HFNO Versus CPAP Helmet) in COVID-19 Pneumonia",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Severe Acute Respiratory Syndrome Coronavirus 2",
        "Hypoxemic Respiratory Failure",
        "Pneumonia, Viral",
        "COVID"
      ],
      "interventions": [
        {
          "name": "Helmet Continuous Positive Airway Pressure (CPAP)",
          "type": "DEVICE"
        },
        {
          "name": "High Flow Nasal Oxygen (HFNO)",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "University of Pennsylvania",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2021-11-15",
      "completion_date": "2022-12-15",
      "has_results": false,
      "last_update_posted_date": "2022-04-05",
      "last_synced_at": "2026-11-05T18:34:45.783Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04381923"
    }
  ]
}